Linagliptin is a dipeptidyl peptidase-4 inhibitor that reduces blood sugar by increasing insulin and decreasing glucagon production by the pancreas, used to treat diabetes mellitus type 2. This evidence concerns the gene DPP4 and diabetes mellitus.